# Dare Bioscience, Inc.: overview DARE · Nasdaq · CIK 1401914 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/dare.md) · [Financials](/companies/dare/financials.md) · [Filings](/companies/dare/filings.md) · [Insiders](/companies/dare/insiders.md) Latest reported revenue: [$187.5k](/filings/0001401914-26-000043.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001401914-26-000043). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [41.7](/filings/0001401914-25-000050.md) | [(63.6) d](/filings/0001401914-26-000004.md) | [25.4](/filings/0001401914-26-000026.md) | [(21.2) d](/filings/0001401914-26-000043.md) | [2.3](/filings/0001401914-25-000050.md) | [1,024 d](/filings/0001401914-26-000004.md) | [152](/filings/0001401914-26-000026.md) | [188](/filings/0001401914-26-000043.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(11228.7%)](/filings/0001401914-25-000050.md) | [8465.8% d](/filings/0001401914-26-000004.md) | [(18016.7%)](/filings/0001401914-26-000026.md) | [18079.5% d](/filings/0001401914-26-000043.md) | [(162340.8%)](/filings/0001401914-25-000050.md) | [(143.7%) d](/filings/0001401914-26-000004.md) | [(1967.1%)](/filings/0001401914-26-000026.md) | [(1582.5%)](/filings/0001401914-26-000043.md) | | Net margin | % | [(11279.4%)](/filings/0001401914-25-000050.md) | [8651.5% d](/filings/0001401914-26-000004.md) | [(17219.1%)](/filings/0001401914-26-000043.md) | [18970.7% d](/filings/0001401914-26-000043.md) | [(157505.1%)](/filings/0001401914-25-000050.md) | [(140.8%) d](/filings/0001401914-26-000004.md) | [(1967.7%)](/filings/0001401914-26-000043.md) | [(1590.4%)](/filings/0001401914-26-000043.md) | | Diluted EPS | $ per share | [(0.55)](/filings/0001401914-25-000050.md) | not reported | [(0.50)](/filings/0001401914-26-000026.md) | [(0.45)](/filings/0001401914-26-000043.md) | [(0.28)](/filings/0001401914-25-000050.md) | not reported | [(0.21)](/filings/0001401914-26-000026.md) | [(0.20)](/filings/0001401914-26-000043.md) | | Free cash flow | $k | [(6,206) d](/filings/0001401914-25-000050.md) | [4,743 d](/filings/0001401914-26-000004.md) | [(5,628)](/filings/0001401914-26-000026.md) | [(5,571) d](/filings/0001401914-26-000043.md) | [(617) d](/filings/0001401914-25-000050.md) | [1,238 d](/filings/0001401914-26-000004.md) | [(5,521)](/filings/0001401914-26-000026.md) | [(6,856) d](/filings/0001401914-26-000043.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001401914-23-000013.md) | [10.0](/filings/0001401914-23-000013.md) | [2.8](/filings/0001401914-25-000012.md) | [0.0](/filings/0001401914-26-000004.md) | [1.0](/filings/0001401914-26-000004.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(313.9%)](/filings/0001401914-24-000016.md) | [(1101.9%)](/filings/0001401914-25-000012.md) | [(239692.2%)](/filings/0001401914-26-000004.md) | [(1315.5%)](/filings/0001401914-26-000004.md) | | Net margin | % | not reported | [(309.5%)](/filings/0001401914-24-000016.md) | [(1074.2%)](/filings/0001401914-25-000012.md) | [(41430.9%)](/filings/0001401914-26-000004.md) | [(1300.7%)](/filings/0001401914-26-000004.md) | | Diluted EPS | $ per share | [(0.63)](/filings/0001401914-23-000013.md) | [(0.37)](/filings/0001401914-24-000016.md) | [(4.15)](/filings/0001401914-25-000012.md) | [(0.48)](/filings/0001401914-26-000004.md) | [(1.20)](/filings/0001401914-26-000004.md) | | Free cash flow | $m | [(28.8)](/filings/0001401914-23-000013.md) | [(18.2)](/filings/0001401914-24-000016.md) | [(39.5)](/filings/0001401914-25-000012.md) | [4.9](/filings/0001401914-26-000004.md) | [(10.3)](/filings/0001401914-26-000004.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dare/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2014-04-15 | [Lilly Eli & Co](/insiders/59478.md) | 10% owner | Purchase (P) | 733,445 | $7.00 | $5.1m | [Form 4](/filings/0001209191-14-027708.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.4m | 640,877 | | Added +178,572 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $295.6k | 140,093 | | Reduced −37,746 | | [US BANCORP \\DE\\](/funds/36104.md) | 2026-06-30 | $255.1k | 120,920 | | Added +29,550 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $192.6k | 91,269 | | Added +25,331 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $135.6k | 64,248 | | Added +47,277 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $100.0k | 47,415 | | Added +23,900 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $76.2k | 36,092 | | New +36,092 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $72.2k | 34,209 | | Added +18,778 | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $31.4k | 14,889 | | Added +250 | | [RAYMOND JAMES FINANCIAL INC](/funds/720005.md) | 2026-06-30 | $31.4k | 14,864 | | Reduced −470 | ## Recent filings [All 771 filings](/companies/dare/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 17:00 ET | [DEF 14A](/filings/0001493152-26-045977.md) | Proxy statement, period 2026-10-06 | 0001493152-26-045977 | | 2026-10-02 | 16:01 ET | [8-K](/filings/0001401914-26-000052.md) | 3.01 Delisting notice | 0001401914-26-000052 | | 2026-10-01 | 09:00 ET | [8-K](/filings/0001493152-26-045275.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-045275 | | 2026-09-11 | 16:29 ET | [8-K](/filings/0001401914-26-000050.md) | 5.03 Amendment to articles or bylaws | 0001401914-26-000050 | | 2026-09-09 | 09:00 ET | [8-K](/filings/0001493152-26-041904.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-041904 | | 2026-08-26 | 17:15 ET | [S-1](/filings/0001493152-26-040265.md) | Registration statement | 0001493152-26-040265 | | 2026-08-17 | 08:35 ET | [8-K](/filings/0001493152-26-038649.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-038649 | | 2026-08-13 | 16:02 ET | [8-K](/filings/0001493152-26-037737.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037737 | | 2026-08-13 | 16:02 ET | [10-Q](/filings/0001401914-26-000043.md) | Quarterly report, period 2026-06-30 | 0001401914-26-000043 | | 2026-07-24 | 09:00 ET | [8-K](/filings/0001493152-26-034483.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-034483 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001401914-26-000004.md), filed Mar 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/023eb534-3a19-44a4-bb24-9da9c089720f) ## About the filer - CIK: 1401914 - Tickers: DARE - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:00 ET. No prices; not investment advice.